Vita Therapeutics is a company out of Johns Hopkins that has a patented cell-based therapy that has shown impressive preclinical curative results in muscular dystrophy. Using induced pluripotent stem cells (iPSCs), they have derived human satellite cells, which have shown the ability to sustainably repair and replace muscle over time. This therapy also has the potential to positively impact all degenerative muscular diseases, chemotherapy-induced cachexia, and geriatric conditions. In addition to this, Vita has a separate molecular compound that have also shown preclinical efficacy in MD (muscular dystrophy) models. The company is currently preparing an IND (Investigational New Drug Application) for its lead therapy with the FDA and plans to submit in 2021. The company recently completed a bridge funding and intends to start a Series A round shortly.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Satellite Cell Therapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):